| Literature DB >> 18755721 |
Abstract
Haemoglobin A(1c) (HbA(1c)) is due to celebrate its 40th birthday. Many people would argue that the clinical studies relating the test to diabetes complications while in its late 20s are likely to be its finest ever achievement. However, this article looks at how HbA(1c) has matured since then and discusses in detail how its many strengths and idiosyncrasies as a marker of glycaemic risk have, as a 30-something, become more clearly understood. As HbA(1c) approaches middle age, this paper also describes how the test appears to be developing a mid-life crisis, as debate over how its results should be expressed seems likely to divide opinion among clinicians for some time to come.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18755721 DOI: 10.1136/jcp.2007.054304
Source DB: PubMed Journal: J Clin Pathol ISSN: 0021-9746 Impact factor: 3.411